Table 3.
Best response rates among all treated patients (N=21) and the prior PD-1 inhibitor subgroup (n=12)
| Prior PD-1 Inhibitor Subgroup | All Treated Patientsa | |||
|---|---|---|---|---|
| (n=12) | (N=21) | |||
|
|
|
|||
| n (%) | 95% CI | n (%) | 95% CI | |
| Overall response rate (CR+PR) | 7 (58) | 28-85 | 14 (67) | 43-85 |
| CR | 1 (8) | 0-38 | 4 (19) | 5-42 |
| PR | 6 (50) | 21-79 | 10 (48) | 26-70 |
| SD | 2 (17) | 2-48 | 4 (19) | 5-42 |
| PD | 3 (25) | 5-57 | 3 (14) | 3-36 |
| Disease control rate (CR+PR+SD) | 9 (75) | 43-95 | 18 (86) | 64-97 |
a
Includes 2 patients counted as responders who had dabrafenib and MEK inhibitor-refractory disease whose disease was unequivocally progressing on combination therapy prior to TIL therapy and who received post-infusion dabrafenib to prevent tumor flare.
CR, complete response; MEK, mitogen-activated protein kinase kinase; PD, progressive disease; PD-1, programmed cell death protein 1; PR, partial response; SD, stable disease.